文献速递基础与转化研究医学人工智能与信息学流行病学与生物统计

贝叶斯网络模型ENDORISK用于子宫内膜癌术前风险分层:开发与验证研究

Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study.
PubMed 文献 · PLoS Med · 2020-05-15

本研究基于贝叶斯网络开发并外部验证了ENDORISK模型,用于术前预测子宫内膜癌患者的淋巴结转移和5年疾病特异性生存。模型纳入术前肿瘤分级、免疫组化标志物、血清CA125、血小板计数、影像学淋巴结增大及宫颈细胞学等预测因子。在MoMaTEC队列中,淋巴结转移和5年DSS的AUC均为0.82;在PIPENDO队列中,5年DSS的AUC为0.84,模型校准良好。

要点

  • ENDORISK模型可个体化预测子宫内膜癌术前淋巴结转移风险。
  • 模型在外部验证队列中区分度良好,AUC为0.82-0.84且校准良好。
  • MoMaTEC队列中55.8%患者被分类为淋巴结转移风险<5%,假阴性率1.6%。

核心结论

  • 贝叶斯网络ENDORISK可整合易获取的多模态生物标志物,用于子宫内膜癌术前个体化风险分层。

研究设计与样本

  • 回顾性多中心队列研究,纳入10家欧洲医院763例子宫内膜癌手术患者,中位年龄65岁(IQR 58-71)。
  • 外部验证采用MoMaTEC前瞻性队列446例挪威患者(中位年龄64岁,IQR 59-74)和PIPENDO前瞻性队列384例荷兰患者(中位年龄66岁,IQR 60-73)。

主要发现

  • MoMaTEC队列中,ENDORISK预测淋巴结转移的AUC为0.82(95%CI 0.76-0.88),预测5年DSS的AUC为0.82(95%CI 0.77-0.87)。
  • PIPENDO队列中,ENDORISK预测5年DSS的AUC为0.84(95%CI 0.78-0.90)。
  • MoMaTEC队列中249例(55.8%)被分类为淋巴结转移风险<5%,假阴性率为1.6%。
  • 网络校准良好。

关键数值与推荐

  • ENDORISK纳入的预测因子包括:术前肿瘤分级、ER/PR/p53/L1CAM免疫组化表达、血清CA125、血小板计数、影像学淋巴结增大及宫颈细胞学。

临床怎么用

  • ENDORISK可用于术前个体化评估子宫内膜癌患者淋巴结转移风险和5年DSS,辅助临床决策。
  • 临床实施前尚需前瞻性可行性研究验证。

局限性

  • 开发队列中使用插补法处理缺失的预测变量。
  • 研究为回顾性设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bayesian networks (BNs) are machine-learning-based computational models that visualize causal relationships and provide insight into the processes underlying disease progression, closely resembling clinical decision-making. Preoperative identification of patients at risk for lymph node metastasis (LNM) is challenging in endometrial cancer, and although several biomarkers are related to LNM, none of them are incorporated in clinical practice. The aim of this study was to develop and externally validate a preoperative BN to predict LNM and outcome in endometrial cancer patients. METHODS AND FINDINGS: Within the European Network for Individualized Treatment of Endometrial Cancer (ENITEC), we performed a retrospective multicenter cohort study including 763 patients, median age 65 years (interquartile range [IQR] 58-71), surgically treated for endometrial cancer between February 1995 and August 2013 at one of the 10 participating European hospitals. A BN was developed using score-based machine learning in addition to expert knowledge. Our main outcome measures were LNM and 5-year disease-specific survival (DSS). Preoperative clinical, histopathological, and molecular biomarkers were included in the network. External validation was performed using 2 prospective study cohorts: the Molecular Markers in Treatment in Endometrial Cancer (MoMaTEC) study cohort, including 446 Norwegian patients, median age 64 years (IQR 59-74), treated between May 2001 and 2010; and the PIpelle Prospective ENDOmetrial carcinoma (PIPENDO) study cohort, including 384 Dutch patients, median age 66 years (IQR 60-73), treated between September 2011 and December 2013. A BN called ENDORISK (preoperative risk stratification in endometrial cancer) was developed including the following predictors: preoperative tumor grade; immunohistochemical expression of estrogen receptor (ER), progesterone receptor (PR), p53, and L1 cell adhesion molecule (L1CAM); cancer antigen 125 serum level; thrombocyte count; imaging results on lymphadenopathy; and cervical cytology. In the MoMaTEC cohort, the area under the curve (AUC) was 0.82 (95% confidence interval [CI] 0.76-0.88) for LNM and 0.82 (95% CI 0.77-0.87) for 5-year DSS. In the PIPENDO cohort, the AUC for 5-year DSS was 0.84 (95% CI 0.78-0.90). The network was well-calibrated. In the MoMaTEC cohort, 249 patients (55.8%) were classified with <5% risk of LNM, with a false-negative rate of 1.6%. A limitation of the study is the use of imputation to correct for missing predictor variables in the development cohort and the retrospective study design. CONCLUSIONS: In this study, we illustrated how BNs can be used for individualizing clinical decision-making in oncology by incorporating easily accessible and multimodal biomarkers. The network shows the complex interactions underlying the carcinogenetic process of endometrial cancer by its graphical representation. A prospective feasibility study will be needed prior to implementation in the clinic.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Reijnen C, Gogou E, Visser NCM, et al. Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study. PLoS Med. 2020. PMID: 32413043. doi:10.1371/journal.pmed.1003111

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。